Hematopoietic stem cell transplantation using single UM171-expanded cord blood
                         CML - Chronic myeloid leukemia

 
''Benefits of cord blood transplantation include low rates of relapse and chronic graft-versus-host disease (GVHD). However, the use of cord blood is rapidly declining because of the high incidence of infections, severe acute GVHD, and transplant-related mortality. UM171, a haematopoietic stem cell self-renewal agonist, has been shown to expand cord blood stem cells and enhance multilineage blood cell reconstitution in mice. We aimed to investigate the safety and feasibility of single UM171-expanded cord blood transplantation in patients with haematological malignancies who do not have a suitable HLA-matched donor.''
​Extract of  Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study
CLINICAL TRIALS

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia
Fred Hutchinson / University of Washington Cancer Consortium
Seattle, Washington, United States

Expanded Cord Blood in Patients in Need of an Allogeneic Stem Cell Transplant
​Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada
                           More clinical trials for UM171